Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma
Latest Information Update: 12 Sep 2025
At a glance
- Drugs JNJ 95597528 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Janssen-Cilag
Most Recent Events
- 12 Sep 2025 New trial record